uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2014 (English)In: Endocrine reviews, ISSN 0163-769X, E-ISSN 1945-7189, Vol. 35, no 3, 341-375 p.Article, review/survey (Refereed) Published
Abstract [en]

Despite the high prevalence of performance-enhancing drug (PED) use, media attention has focused almost entirely on PED use by elite athletes to illicitly gain a competitive advantage in sports, and not on the health risks of PEDs. There is a widespread misperception that PED use is safe or that adverse effects are manageable. In reality, the vast majority of PED users are not athletes but rather nonathlete weightlifters, and the adverse health effects of PED use are greatly under appreciated. This scientific statement synthesizes available information on the medical consequences of PED use, identifies gaps in knowledge, and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem. PED users frequently consume highly supraphysiologic doses of PEDs, combine them with other PEDs and/or other classical drugs of abuse, and display additional associated risk factors. PED use has been linked to an increased risk of death and a wide variety of cardiovascular, psychiatric, metabolic, endocrine, neurologic, infectious, hepatic, renal, and musculoskeletal disorders. Because randomized trials cannot ethically duplicate the large doses of PEDs and the many factors associated with PED use, we need observational studies to collect valid out come data on the health risks associated with PEDs. In addition, we need studies regarding the prevalence of PED use, the mechanisms by which PEDs exert their adverse health effects, and the interactive effects of PEDs with sports injuries and other high-risk behaviors. We also need randomized trials to assess therapeutic interventions for treating the adverse effects of PEDs, such as the anabolic-androgen steroid withdrawal syndrome. Finally, we need to raise public awareness of the serious health consequences of PEDs.

Place, publisher, year, edition, pages
2014. Vol. 35, no 3, 341-375 p.
National Category
Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-228889DOI: 10.1210/er.2013-1058ISI: 000337500600001OAI: oai:DiVA.org:uu-228889DiVA: diva2:735120
Available from: 2014-07-23 Created: 2014-07-22 Last updated: 2014-07-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Nyberg, Fred
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Endocrine reviews
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 153 hits
ReferencesLink to record
Permanent link

Direct link